| Treatment decisions should follow a shared decision-making process.                                                                            |
| Treatment decisions should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen.               |
| Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).                                   |